1. Home
  2. RPTX vs NSRX Comparison

RPTX vs NSRX Comparison

Compare RPTX & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RPTX
  • NSRX
  • Stock Information
  • Founded
  • RPTX 2016
  • NSRX 2019
  • Country
  • RPTX Canada
  • NSRX Israel
  • Employees
  • RPTX N/A
  • NSRX N/A
  • Industry
  • RPTX Biotechnology: Pharmaceutical Preparations
  • NSRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • RPTX Health Care
  • NSRX Health Care
  • Exchange
  • RPTX Nasdaq
  • NSRX Nasdaq
  • Market Cap
  • RPTX 78.2M
  • NSRX 73.0M
  • IPO Year
  • RPTX 2020
  • NSRX 2025
  • Fundamental
  • Price
  • RPTX $1.95
  • NSRX $7.60
  • Analyst Decision
  • RPTX Strong Buy
  • NSRX Strong Buy
  • Analyst Count
  • RPTX 3
  • NSRX 1
  • Target Price
  • RPTX $4.50
  • NSRX $22.00
  • AVG Volume (30 Days)
  • RPTX 192.1K
  • NSRX 32.2K
  • Earning Date
  • RPTX 11-07-2025
  • NSRX 11-20-2025
  • Dividend Yield
  • RPTX N/A
  • NSRX N/A
  • EPS Growth
  • RPTX N/A
  • NSRX N/A
  • EPS
  • RPTX N/A
  • NSRX N/A
  • Revenue
  • RPTX $250,000.00
  • NSRX N/A
  • Revenue This Year
  • RPTX N/A
  • NSRX N/A
  • Revenue Next Year
  • RPTX N/A
  • NSRX N/A
  • P/E Ratio
  • RPTX N/A
  • NSRX N/A
  • Revenue Growth
  • RPTX N/A
  • NSRX N/A
  • 52 Week Low
  • RPTX $0.89
  • NSRX $5.90
  • 52 Week High
  • RPTX $4.07
  • NSRX $9.99
  • Technical
  • Relative Strength Index (RSI)
  • RPTX 68.62
  • NSRX N/A
  • Support Level
  • RPTX $1.74
  • NSRX N/A
  • Resistance Level
  • RPTX $1.97
  • NSRX N/A
  • Average True Range (ATR)
  • RPTX 0.08
  • NSRX 0.00
  • MACD
  • RPTX 0.01
  • NSRX 0.00
  • Stochastic Oscillator
  • RPTX 91.49
  • NSRX 0.00

About RPTX Repare Therapeutics Inc.

Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.

Share on Social Networks: